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It has been hypothesized that concentrations of exhaled nitric oxide (NO) may be related to the extent of 
cytokine-mediated airway inflammation. Recent findings indicate the nasal airways as an important site of NO 
production. 
Our objective was to evaluate whether children with allergic rhinitis show different nasal NO levels when 
compared with normal healthy subjects and the effect of topical steroids and anti-histamine therapy. 
We have measured the concentration of NO drawn from the nose of 21 children (5-17 years old) affected by 
perennial allergic rhinitis (house dust mite) out of therapy for at least 3 weeks. Thirteen children were then treated 
with nasal beclomethasone dipropionate (BDP) (400 ug daily) and eight subjects with nasal anti-histamine 
levocabastine (200 ug daily). Measurements were performed before and after 10 days of treatment. As a control 
group we evaluated 21 healthy children aged 5-15 years. To measure NO we used a chemiluminescence analyser. 
Before treatment the whole group of children with allergic rhinitis showed a mean (* SEM) nasal NO 
concentration of 267 f 18 ppb, significantly higher (PcO.01) than the control group (186 * 15 ppb). The group 
of children treated with BDP showed, after 10 days of therapy, a significant (P<O.O5) decrease of nasal NO 
concentration (271 & 21 ppb vs. 212 & 20 ppb). Indeed, in the group treated with levocabastine, nasal NO 
concentrations did not present a significant difference (P not significant) compared with baseline (261 f 33 ppb and 
252 * 3 1 ppb, respectively). 
These data suggest that (1) children with allergic rhinitis have higher levels of nasal NO than non-atopic controls 
and (2) intranasal steroid therapy significantly reduces nasal NO production in children with allergic rhinitis. We 
speculate that the allergic inflammatory response may influence the nasal NO levels and that NO measurements may 
be a useful marker of nasal inflammation. 
RESPIR. MED. (1998) 92, 558-561 
Introduction 
Nitric Oxide (NO) is a gas produced in mammalian airways 
and there is convincing evidence that it plays a key role in 
the regulation of a wide variety of airway functions. NO is 
derived from the guanidine nitrogen of L-arginine by the 
action of nitric oxide synthase (NOS), which exists in 
constitutive (cNOS) and inducible (iNOS) isoforms (1). The 
cNOS isoforms produce small amounts of NO which act 
locally. cNOS isoforms are expressed in endothelial cells 
(type III NOS), in the peripheral nervous system (type I 
NOS) and in other cells such as neutrophils, platelets and 
mast cells (2). The NO produced by these cNOS isoforms 
has a predominant role of a homeostatic molecule and it is 
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mainly involved as mediator in the endothelium-dependent 
vasodilatation and in the regulation of airway tone. The 
iNOS isoforms (type II NOS) are calcium-independent 
enzymes and may be expressed after exposure to pro- 
inflammatory cytokines as well as to endotoxin or to 
oxidant substances. Induction of iNOS produces larger 
amounts of NO than the activation of cNOS. iNOS has 
been described in macrophages, epithelial cells, smooth 
muscle cells, endothelial cells and neutrophils. Steroids 
inhibit the induction of iNOS but have no effect on cNOS 
(1). 
A number of observations determined that NO content in 
the expired air of asthmatics who were not receiving 
treatment with glucocorticoids was greater than exhaled 
NO of normal subjects and of asthmatics treated with 
steroids (3). This finding, coupled with the demonstration 
of enhanced type II NOS immunoreactivity in the airway 
epithelium of patients with asthma (4), raised the interesting 
possibility that measurement of exhaled NO could be a 
useful index of airway inflammation. 
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High concentrations of NO have been detected in the 
nose and it has been suggested that it is produced by the 
nasopharyngeal mucosa (5). Recently immunocytochemical 
studies of nasal biopsies have identified the presence of 
iNOS also in the human nasal mucosa (6) and a possible 
role for type II NO synthase in mediating the inflammatory 
response of nasal mucosa has been suggested. 
Few studies have evaluated the role of NO in patients 
with allergic rhinitis (78) and the effect of therapy on NO 
production is not defined yet. The aim of this study is to 
evaluate (1) whether children with perennial allergic rhinitis 
show different nasal NO levels when compared with normal 
healthy subjects and (2) whether a topical course of steroid 
and anti-histamine treatments may alter nasal NO levels. 
Patients and Methods 
The study was performed in 21 children (mean age 9.6 f 0.6 
years, range 5-17 years) with allergic rhinitis for at least 
2 yr. Children were eligible for our study if affected by 
perennial allergic rhinitis with characteristic symptoms 
(nasal pruritus, sneezing, rhinorrhoea, obstruction) and a 
positive skin test (>3 mm wheal) for Dermatophagoides 
pteronyssinus and Dermatophagoides farinae. Exclusion cri- 
teria from the study included a concomitant allergy to 
seasonal pollens, treatment with any drugs and/or infection 
of the upper respiratory tract in the 3 weeks previous to the 
study. All children attended the Paediatric Pulmonology- 
Allergology outpatient clinic of the Department of Paedi- 
atrics of Padova. 
Children were randomly allocated to receive a 10 day 
course of (1) a topical glucocorticoid, beclomethasone 
dipropionate nasal spray (BDP group) or (2) a topical 
anti-histamine drug, levocabastine nasal spray (anti-H 
group). Children of the BDP group were treated with a 
dosage of 200 ug twice daily of beclomethasone nasal spray 
(Becotidea”, Glaxo) and children of the anti-H group with a 
dosage 100 ug twice daily of levocabastine nasal spray 
(Levostab:@, Janssen). 
Evaluation of therapeutic efficacy was based on assess- 
ment of the severity of a number of nasal symptoms 
(sneezing, rhinorrhoea, pruritus and congestion). A point 
scale was used at the start of the trial and after 10 days of 
treatment by the investigator for evaluation of symptoms 
according to a O-3 grading (0, absent; 1, mild; 2, moderate; 
3, severe). Using the same scale, patients were instructed to 
keep a diary for the daily evaluation of symptoms. 
As a control group normal healthy children (mean age 
10.5 f 0.5 years, range 5-15 years) with a negative history 
of allergic disease or recurrent rhinitis were enrolled. All 
children had to be disease free in the last 3 weeks prior 
recruitment. 
Nasal NO concentrations were determined from the air 
drawn from the nose of all included children. Measure- 
ments were performed at baseline and after 10 days of 
treatment in the affected children. The investigator who 
performed the measurements of NO (N.M.A.) was blinded 
regarding the treatment used. At each measurement the 
children were asked to take a deep inspiration, to close the 
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TABLE 1. Patients’ characteristics 
Sex 
Subjects Number Age (years) M F 
Allergic rhinitis 2 1 9.6 z!r 0.6 (5-17) 17 4 
BDP group 13 lo&o.8 (5-17)* 11 2 
Anti-H group 8 85*0.7(&11)* 7 1 
Controls 21 10.5 +Z 0.5 (5515) 18 3 
BDP group: beclomethasone dipropionate 400 ug day - ‘. 
Anti-H group: levocabastine 200 ug day- ‘. 
*P=not significant. 
mouth and to hold the breath for 25 s. A nasal occluding 
olive was placed into the vestibulum of one nostril during 
the procedure and air samples were continuously collected 
by a short sealing Teflon tube connected to the NO 
analyser. The peak NO levels obtained after 25 s of breath 
holding were recorded. The contralateral nostril was left 
open. Two measurements were made on each session and 
the mean was considered for analysis. We used a chemi- 
luminescence analyser (Orion, Rotork 447, England) sensi- 
tive to NO from 1 to 1000 ppb, adapted for on-line 
recording of NO concentration. The chemiluminescence 
analyser was calibrated with a certified calibration mixture 
of NO (Air Liquid, Milano, Italy). In healthy children NO 
levels were also measured in the air exhaled from the mouth 
during tidal volume breathing using an open circuit. The 
study was approved by the medical committee of our 
University Hospital and all patients gave informed 
consent. 
All mean NO concentrations are reported in parts per 
billion with the corresponding standard error of the mean 
(mean f SEM). As statistical tests Wilcoxon’s matched-pair 
test and the Mann-Whitney rank sum test were used; a 
P value lower than 0.05 was considered as significant. 
Results 
Twenty-one children with allergic rhinitis and 21 healthy 
controls were included in the study. Patients’ characteristics 
are presented in Table 1. Of the children with allergic 
rhinitis, 20 completed the study because one patient of the 
anti-H group withdraw. Of these, 13 received beclometha- 
sone dipropionate (BDP group) while seven were given 
levocabastine (anti-H group). The main results are pre- 
sented in Table 2. Investigator assessments of score symp- 
toms (total nasal symptoms) at the start of the study (7.5 in 
the BDP group and 7.2 in the levocabastine group) were not 
different in the two groups (P not significant), Mean 
baseline measurement of nasal NO in the 21 affected 
children was 267 & 18 ppb while in the control group it 
was 186 * 15 ppb. The difference is statistically significant 
(P<O.Ol). NO baseline values of the BDP group 
(271 f 21 ppb) and the anti-H group (261 & 33 ppb) did not 
show a significant difference (P not significant) (Table 2). 
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TABLE 2. Main results: concentrations of nasal NO 
expressed in ppb in children with allergic rhinitis and 
controls 
Subjects Baseline 
After 10 days 
of therapy P value 
Allergic rhinitis 
(whole group) 
BDP group 
Anti-H group 
Control group 
267 zt 18* 
271 f 21** 212 * 20 co.01 
261 f 33 252 zk 31 n.s. 
186 f 15 
*P<O.Ol: allergic rhinitis (whole group) vs. control group. 
**P=not significant: BDP group vs. anti-H group, baseline 
values. 
No significant correlation was found between nasal 
symptoms and nasal NO values (P not significant). 
After nasal BDP treatment (BDP group) NO levels 
decreased to 212 f 20 ppb with a statistically significant 
difference with pretreatment values (PcO.05). After levoca- 
bastine treatment (anti-H group) NO levels detected were 
equal to 252 f 31 ppb, a value not significantly different 
when compared with pretreatment values (P not significant). 
The results of treatment efficacy based on the clinical 
score demonstrated a significant trend in favour of BDP 
(2.8 in the BDP group and 5.6 in the levocabastine group, 
PcO.01). NO levels obtained from air exhaled from the 
mouths of the control group were equal to 11 f 4 ppb, sig- 
nificantly (P<O.OOl) lower than nose values (186 f 15 ppb). 
Discussion 
NO has been identified as an important mediator in numer- 
ous physiological and inflammatory processes in the 
respiratory system and it seems to be involved in the 
pathophysiology of several airway diseases (1). The exact 
NO production site in the respiratory airways is not defi- 
nitely established. There is persuasive evidence that in the 
nasal mucosa there is a production of NO that is easily 
measurable in the nasal cavity (5). Nasal nebulization of 
NOS inhibitors such as L-arginine analogues (L-NAMES), 
that act as false substrate for the enzyme, causes a signifi- 
cant reduction of nasal NO levels while L-arginine nebuli- 
zation (precursor of NO synthesis) provokes a restoration 
of nasal NO concentration (9). Furthermore, the presence 
of the NOS enzymes has been demonstrated in the 
epithelium of human nasal mucosa, of both healthy and 
rhinitic subjects, using immunohistochemistry (6,lO). 
The results of our study show that NO nasal levels 
measured in children affected by allergic rhinitis are signifi- 
cantly higher compared with healthy control children 
(267 ppb vs. 186 ppb). The role of NO in allergic rhinitis is 
undefined; it can be speculated that high nasal NO levels 
are determined by the expression of iNOS in the nasal 
mucosa possibly induced by the cytokines of the allergic 
reaction, as is described for asthmatic flogosis (3). This 
hypothesis is supported by the significant correlation found 
by Furukawa et al. (6) between the extent of nasal inflam- 
mation and the cellular expression of NOS in patients with 
chronic rhinitis and by the preliminary data of Springall 
et al. (11) showing an upregulated expression of iNOS in 
nasal biopsies of patients with allergic rhinitis. NO nasal 
measurement in subjects with allergic rhinitis could there- 
fore similarly represent an index of local allergic inflamma- 
tion in asthmatic patients. Our findings are consistent with 
results of one previous study (8) in which exhaled levels of 
NO were determined in adult patients with seasonal allergic 
rhinitis during the grass pollen season and compared with 
non-atopic individuals. These authors (8) found that, in the 
subjects with seasonal rhinitis, levels of exhaled NO were 
significantly higher both in nasally exhaled air and in orally 
exhaled air compared with non-atopic individuals, suggest- 
ing generalized inflammation of the airways in patients with 
rhinitis but no obvious evidence of clinical asthma. Also, 
these authors hypothesized that the high levels of nasal 
NO could be consistent with induction of iNOS in associ- 
ation with mucosal mast cell, eosinophil and T-lymphocyte 
activation. 
The second main finding of our study is about the effect 
of topical therapy on nasal NO production. Up-to-date 
treatment of allergic rhinitis includes, in addition to remov- 
ing the specific allergen, the usage of topical or systemic 
drugs such as corticosteroids, anti-histamine compounds, 
sodium cromoglycate and anticholinergics (12). The most 
efficacious drugs on symptoms (nasal itching, sneezing, 
closing nose) are anti-histamine and corticosteroid drugs. 
Recently, levocabastine, an HI-receptor antagonist 
designed for topical application, has been proposed as a 
valid alternative to oral antihistamines (13). 
Rhinitic children given topical glucocorticoids (BDP 
group) presented a significant reduction of nasal NO levels 
compared with baseline values after 10 days of treatment. 
On the contrary, no significant difference in nasal NO has 
been detected in children treated with levocabastine, a 
recent HI-receptor antagonist. However, regarding the 
comparison of inhaled steroids and anti-histamine drugs of 
the present study, we believe that no definitive conclusion 
can be reached because of the limited sample size of these 
subgroups which may have entailed insufficient statistical 
power. Regarding the changes of nasal NO after BDP 
treatment it can be speculated that the anti-inflammatory 
effect of glucocorticoids results in a downregulation of the 
transcription of iNOS with subsequent reduced values of 
nasal NO levels. This hypothesis has not yet been demon- 
strated but it has been shown that corticosteroids inhibit 
the expression of iNOS probably by blocking the transcrip- 
tion factor nuclear factor K B that is critical for transcrip- 
tion of the iNOS gene (14). The reduction of nasal NO after 
nasal steroids found in our study is in agreement with 
preliminary data of Kharitonov et al. in adult patients with 
allergic rhinitis treated with inhaled steroids (15) and to our 
knowledge this is the first study in children. Different 
conclusions were obtained by a Dutch group that recently 
reported that 2 weeks of therapy with a new topical steroid 
(fluticasone propionate) was ineffective in changing 
NO nasal production in subjects with allergic rhinitis (7). 
However, these authors did not measure NO concen- 
trations directly in nasal cavities but determined NO 
metabolites (nitrites and nitrates) in nasal wash material. 
In conclusions these data suggest that (1) children with 
allergic rhinitis have higher levels of nasal NO than non- 
atopic controls and (2) intranasal steroid therapy signifi- 
cantly reduces nasal NO production in children with 
allergic rhinitis. Although further studies are required to 
confirm these preliminary data, we speculate that, in 
allergic rhinitis, NO nasal levels can be considered a useful 
marker of allergic immunoflogosis and its measurement an 
easy method for monitoring the response to therapy. 
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